Methicillin-resistant Staphylococcus aureus infections in ICU patients

Anesthesiology Clinics of North America

Volumn 22, Issue 3, 2004, Pages 405-435

  Sista, Ramachandra R ^a   Oda, Gina ^b   Barr, Juliana ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; CEFAZOLIN; CEPHALOSPORIN; CHLORAMPHENICOL; COTRIMOXAZOLE; CYCLOSPORIN; DALFOPRISTIN; DAPTOMYCIN; DOBUTAMINE; DOPAMINE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; KANAMYCIN; LINEZOLID; METICILLIN; MIDAZOLAM; NAFCILLIN; NIFEDIPINE; NORADRENALIN; PENICILLIN G; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; STREPTOMYCIN; TERFENADINE; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANAPHYLAXIS; ANEMIA; ARTHRALGIA; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; ENZYME SYNTHESIS; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PATHOGENESIS; PHLEBITIS; RASH; REVIEW; RISK FACTOR; SEROTONIN SYNDROME; SKIN IRRITATION; SKIN TINGLING; SURGICAL INFECTION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VOMITING;

BACTEREMIA; CROSS INFECTION; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; METHICILLIN RESISTANCE; PNEUMONIA, STAPHYLOCOCCAL; POSTOPERATIVE COMPLICATIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 4344602968     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atc.2004.04.006     Document Type: Review

References (158)

1. Novick R.P. The staphylococcus as a molecular genetic system. Novick R.P. Molecular biology of the Staphylococci. 1990;1-37 Wiley-VCH, New York
2. Schaberg D.R., Zervos M.J. Intergeneric and interspecies gene exchange in gram-positive cocci. Antimicrob Agents Chemother. 30:1986;817-822
3. Koneman E.W., Allen S.D., Janda W.M., Schreckenberger P.C., Winn W.C. The gram-positive cocci. Part 1: Staphylococci and related organisms. Koneman E.W., Allen S.D., Janda W.M., Schreckenberger P.C., Winn W.C. Color atlas and textbook of diagnostic microbiology. 5th edition:1997;539-596 Lippincott, Philadelphia
4. Waldvogel F.A. Staphylococcus aureus (including staphylococcal toxic shock). Mandell G.L., Bennett J.E., Dolin R. Principles and practice of infectious diseases. 5th edition:2000;2069-2092 Churchill Livingstone, New York
5. Projan S.J., Novick R.P. The molecular basis of pathogenicity. Crossley K.B., Archer G.L. The Staphylococci in human disease. 1997;55-81 Churchill Livingstone, New York
6. Lina G., Piemont Y., Godail-Gamot F., Bes M., Peter M.O., Gauduchon V., et al. Involvement of Panton-Valentine Leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 29:1999;1128-1132
7. Gillet Y., Issartel B., Vanhems P., Fournet J.C., Lina G., Bes M., et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet. 359:2002;753-759
8. Marrack P., Kappler J. The Staphylococcal enterotoxins and their relatives. Science. 248:1990;705-711
9. Marrack P., Kappler J. The staphylococcal enterotoxins and their relatives. Science. 248:1990;705-711. erratum: Science 1990;248:1066
10. Waldvogel F.A. Staphylococcus aureus (including toxic shock syndrome). In: Mandell G.L., Bennett J.E., Dolin R., editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th edition. Volume 2. New York: Churchill Livingstone; 1995. p. 1754-77
11. Foster T.J., Hartford L., O'Donnell D. Host-pathogen, protein-protein interactions in staphylococcus. McCrae M.A., Saunders J.R., Smyth C.J., Stow N.D. Molecular aspects of host-pathogen interaction. 1997;67-94 Cambridge University Press, Cambridge (UK)
12. Crossley K.B., Archer G.L. The Staphylococci in human disease. 1997;Churchill Livingstone, New York
13. Casewell M.W., Hill R.L.R. The carrier state. MRSA. J Antimicrob Chemother. 18(Suppl A):1986;S1-S12
14. Elek S.D., Conen P.E. The virulence of S. pyogenes for man: a study of the problems of wound infection. Br J Exp Pathol. 38:1957;573-586
15. Zimmerli W., Lew P.D., Waldvogel F.A. Pathogenesis of foreign body infection: evidence for a local granulocyte defect. J Clin Invest. 73:1984;1191-1200
16. Procter R.A., van Langevelde P., Kristjansson M., Maslow J.N., Arbeit R.D. Persistent and relapsing infections associated with small-colony variants of S. aureus. Clin Infect Dis. 20:1995;95-102
17. Timmerman C.P., Mattsson E., Martinez-Martinez L., De Graaf L., Van Strijp J.A., Verbrugh H.A., et al. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun. 61:1993;4167-4172
18. Heumann D., Barras C., Severin A., Glauser M.P., Tomasz A. Gram positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun. 62:1994;2715-2721
19. Bone R.C. Gram-positive organisms and sepsis. Arch Intern Med. 154:1994;26-34
20. Bohach G.A., Fast D.J., Nelson R.D., Schlievert P.M. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol. 17:1990;251-272
21. Foster T. Staphylococcus. Baron S. Medical microbiology. 1996;University of Texas Medical Branch, Galveston (TX)
22. Tomasz A., Drugeion H.B., de Lencastre H.M., Jabes D., McDougall L., Bille J. New mechanism for methicillin resistance in staphylococcus aureus: clinical isolates that lack the PBP 2a gene and contain normal PBPs with modified penicillin-binding capacity. Antimicrob Agents Chemother. 33:1989;1869-1874
23. McDougall L., Thornsberry C. The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephaalosporins. J Clin Microbiol. 23:1986;832-839
24. Chambers H.F., Archer G., Matsuhashi M. Low-level methicillin resistance in strains of S. aureus. Antimicrob Agents Chemother. 33:1989;424-428
25. Hirano L., Bayer A.S. Beta-lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase- producing oxacillin-resistant staphylococci. Antimicrob Agents Chemother. 35:1991;685-690
26. Hawkey P.M. Quinolones in sweat and quinolone resistance. Lancet. 349:1997;148-149
27. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136
28. Update. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep. 46:1997;813-815. erratum: MMWR 1997;46:851
29. Sievert D.M., Boulton M.L., Stoltman G. Staphylococcus aureus resistant to vancomycin - United States, 2002. Centers for Disease Control. MMWR Morb Mortal Wkly Rep. 51:2002;565-567
30. Public Health Dispatch Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. Centers for Disease Control. MMWR Morb Mortal Wkly Rep. 51:2002;902
31. Sieradzki K., Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol. 179:1997;2557-2566
32. Noble W.C., Virani Z., Cree R.G. Co-transfer of vancomycin and other resistance genes from Enterococcus fecalis NCTC 12201 to S. aureus. FEMS Microbiol Lett. 72:1992;195-198
33. Casewell M.W., Hill R.L.R. The carrier state: methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 18(Suppl A):1986;1-12
34. Noble W.C., Valkenburg H.A., Wolters C.H.L. Carriage of Staphylococcus aureus in random samples of a normal population. J Hyg (Lond). 65:1967;567-573
35. Sanford M.D., Widmer A.F., Bale M.J., Jones R.N., Wenzel R.P. Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 19:1994;1123-1128
36. Wenzel R.P., Perl T.M. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect. 31:1995;13-24
37. Centers for Disease Control Methicillin-resistant Staphylococcus aureus infections among competitive sports participants - Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep. 52:2003;793-795
38. Mulhausen P.L., Harrell L.F., Weinberger M., Kochersberger G.G., Feussner J.R. Contrasting methicillin-resistant staphylococcus aureus colonization in Veterans Affairs and community nursing homes. Am J Med. 100:1996;24-31
39. Acquisition of methicillin-resistant Staphylococcus aureus in a large intensive care unit. Infect Control Hosp Epidemiol. 24:2003;322-326
40. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control. 31:2003;481-498
41. CDC NNIS personnel National Nosocomial Infections Surveillance (NNIS) System report data, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control. 29:2001;404-421
42. MRSA-Methicillin Resistant Staphylococcus Aureus, In: Issues in Healthcare Settings. http://www.cdc.gov/ncidod/hip/ARESIST/mrsa.htm. Accessed March 10, 2004
43. Vincent J.-L., Bihari D.J., Suter P.M., Bruining H.A., White J., Nicolas-Chanoin M.H., et al. The prevalence of nosocomial infection in ICUs in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. JAMA. 274:1995;639-644
44. Rodman D.P., Mc Knight J.T., Rogers T., Robbins M. Initial vancomycin dosages in a community/teaching hospital. J Fam Pract. 38:1994;473-478
45. Lodise T.P., McKinnon P.S., Swiderski L., Rybak M.J. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 36:2003;1418-1423
46. Niederman M.S. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med. 29(Suppl):2001;N114-N120
47. Tuazon C.U., Perez A., Kishaba T., Sheagren J.N. Staphylococcus aureus among insulin-injecting diabetic patients: an increased carrier rate. JAMA. 231:1975;1272
48. Tuazon C.U., Sheagren J.N. Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis. 129:1974;725-727
49. Yu V.L., Goetz A., Wagener M., Smith P.B., Rihs J.D., Hanchett J., et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis: efficacy of antibiotic prophylaxis. N Engl J Med. 315:1986;91-96
50. Weinstein H.J. The relation between the nasal-staphylococcal-carrier state and the incidence of postoperative complications. N Engl J Med. 260:1959;1303-1308
51. Kluytmans J.A., Mouton J.W., Ijzerman E.P., Vandenbroucke-Grauls C.M., Maat A.W., Wagenvoort J.H., et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis. 171:1995;216-219
52. Weinke T., Schiller R., Fehrenbach F.J., Pohle H.D. Association between Staphylococcus aureus nasopharyngeal colonization and septicemia in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis. 11:1992;985-989
53. Lucet J.-C., Chevret C., Zaleski-Durand I., Chastang C. Regnier B for the Multicenter Study Group Prevalence and risk factors for carriage of MRSA at admission to the ICU. Arch Intern Med. 163:2003;181-188
54. Eguia J.M., Chambers H.F. MRSA their treatment in the ICU. Semin Respir Crit Care Med. 24:2003;37-47
55. Ho P.L. For the Hong Kong intensive care unit antimicrobial resistance study (HK-ICARE) Group Carriage of methicillin-resistant staphylococcus aureus, ceftazidime-resistant gram-negative bacilli, and vancomycin-resistant enterococci before and after intensive care unit admission. Crit Care Med. 31:2003;1175-1182
56. Theaker C., Ormond-Walshe S., Azadian B., Soni N. MRSA in the critically ill. J Hosp Infect. 48:2001;98-102
57. Blot S.I., Vandewoude K.H., Hoste E.A., Colardyn F.A. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med. 162:2002;2229-2235
58. Pujol M., Pena C., Pallares R., Ariza J., Ayats J., Dominguez M.A., et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med. 100:1996;509-516
59. Community-associated MRSA, frequently asked questions. www.cdc.gov/ncidod/hip/ARESIST/mrsa_comm_faq_print.htm. Accessed March 8, 2004
60. Embil J., Ramotar K., Romance L., Alfa M., Conly J., Cronk S., et al. Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies 1990-1992. Infect Infect Control Hosp Epidemiol. 15:1994;646-651
61. Rings T., Findlay R., Lang S. Ethnicity and methicillin-resistant S. aureus in South Auckland. N Z Med J. 111:1998;151
62. Maguire G.P., Arthur A.D., Boustead P.J., Dwyer B., Currie B.J. Emerging epidemic of community-acquired methicillin-resistant Staphylococcus aureus infection in the Northern Territory. Med J Aust. 164:1996;721-723
63. Collignon P., Gosbell I., Vickery A., Nimmo G., Stylianopoulos T., Gottlieb T. Community-acquired methicillin-resistant Staphylococcus aureus MRSA in Australia. Australian Group on Antimicrobial Resistance. Lancet. 352:1998;145-146
64. Pujol M., Corbella X., Pena C., Pallares R., Dorca J., Verdaguer R., et al. Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur J Clin Microbiol Infect Dis. 17:1998;622-628
65. Ibrahim E.H., Ward S., Sherman G., Kollef M.H. A comparative analysis of patients with early-onset vs. late-onset nosocomial pneumonia in the ICU setting. Chest. 117:2000;1434-1442
66. Gonzalez C., Rubio M., Romero-Vivas J., Gonzalez M., Picazo J.J. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis. 29:1999;1171-1177
67. Rello J., Torres A., Ricart M., Valles J., Gonzalez J., Artigas A., et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med. 150:1994;1545-1549
68. Georges H., Leroy O., Alfandari S., Guery B., Roussel-Delvallez M., Dhennain C., et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis. 16:1997;385-388
69. Small P.M., Chambers H.F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 34:1990;1227-1231
70. Tablan O.C., Anderson L.J., Arden N.H., Breiman R.F., Butler J.C., McNeil M.M. Guideline for prevention of nosocomial pneumonia. The Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Infect Control Hosp Epidemiol. 15:1994;587-627
71. Rello J., Diaz E. Pneumonia in the intensive care unit. Crit Care Med. 31:2003;2544-2551
72. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 29:1999;239-244
73. Petti C.A., Fowler V.G. Jr. Staphylococcus aureus bacteremia and endocarditis. Infect Dis Clin North Am. 16:2002;413-435
74. Mylotte J.M., McDermott C., Spooner J.A. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis. 9:1987;891-907
75. Ing M.B., Baddour L.M., Bayer A.S. Bacteremia and infective endocarditis: pathogenesis, diagnosis, and complications. Crossley K.B., Archer G.L. The staphylococci in human disease. 1997;331-354 Churchill Livingstone, New York
76. Sanabria T.J., Alpert J.S., Goldberg R., Pape L.A., Cheeseman S.H. Increasing frequency of staphylococcal infective endocarditis: experience at a university hospital, 1981 through 1988. Arch Intern Med. 150:1990;1305-1309
77. Libman H., Arbeit R.D. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med. 144:1984;541-545
78. Jernigan J.A., Farr B.M. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med. 119:1993;304-311
79. Espersen F., Frimodt-Møller N. Staphylococcus aureus endocarditis: a review of 119 cases. Arch Intern Med. 146:1986;1118-1121
80. Fang G., Keys T.F., Gentry L.O., Harris A.A., Rivera N., Getz K., et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia. A prospective, multicenter study. Ann Intern Med. 119:1993;560-567
81. Whitby M., Mc Laws M.L., Berry G. Risk of death from methicillin- resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust. 175:2001;264-267
82. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 36:2003;53-59
83. Pujol M., Pena C., Pallares R., Ayats J., Gudiol F. Risk factors for nosocomial bacteraemia due to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 13:1994;96-102
84. Steinberg J.P., Clark C.C., Hackman B.O. Nosocomial and community acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis. 23:1996;255-259
85. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. National Nosocomial Infections Surveillance System. Crit Care Med. 27:1999;887-892
86. von Eiff C., Becker K., Machka K., Stammer H., Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med. 344:2001;11-16
87. Raad I.I., Sabbagh M.F. Optimal duration of therapy of catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis. 14:1992;75-82
88. Petti C.A., Fowler V.G. Staphylococcus aureus bacteremia and endocarditis. Cardiol Clin. 21(2):2003;219-233
89. Fowler V.G., Li J., Corey G.R., Boley J., Marr K.A., Gopal A.K., et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol. 30:1997;1072-1078
90. Centers for Disease Control and Prevention Guidelines for the prevention of intravascular catheter-related infections. MMWR Morb Mortal Wkly Rep. 51:2002;1-29
91. Manian F.A., Meyer P.L., Setzer J., Senkel D. Surgical site infections associated with methicillin-resistant Staphylococcus aureus: do postoperative factors play a role? Clin Infect Dis. 36:2003;863-868
92. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., Jarvis W.R. the Hospital Infection Control Practices Advisory Committee Guidelines for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol. 20:1999;247-278
93. SHEA, APIC, CDC, SIS Consensus paper on the surveillance of surgical wound infections. Infect Control Hosp Epidemiol. 13:1992;599-605
94. Cruse P.J. Surgical wound infection. Wonsiewicz M.J. Infectious diseases. 1992;758-764 WB Saunders, Philadelphia
95. Mekontso-Dessap A., Kirsch M., Brun-Buisson C., Loisance D. Poststernotomy mediastinitis due to Staphylococcus aureus: comparison of methicillin-resistant and methicillin-susceptible cases. Clin Infect Dis. 32:2001;877-883
96. Engemann J.J., Carmeli Y., Cosgrove S.E., Fowler V.G., Bronstein M.Z., Trivette S.L., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 36:2003;592-598
97. Perl T.M., Cullen J.J., Wenzel R.P., Zimmerman M.B., Pfaller M.A., Sheppard D., et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 346:2002;1871-1877
98. Frank S.M., Beattie C., Christopherson R., Norris E.J., Rock P., Parker S. Epidural versus general anesthesia, ambient operating room temperature, and patient age as predictors of inadvertent hypothermia. Anesthesiology. 77:1992;252-257
99. Sessler D.I. Mild perioperative hypothermia. N Engl J Med. 336:1997;1730-1737
100. Hopf H.W., Hunt T.K., West J.M., Bloomquist P., Goodson W.H. III, Jensen J.A., et al. Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg. 132:1997;997-1004
101. Kurz A., Sessler D.I., Lenhardt R. Perioperative normothermia to reduce the incidence of surgical wound infection and shorten hospitalization: study of wound Infection and temperature group. N Engl J Med. 334:1996;1209-1215
102. Greif R., Akca O., Horn E.P., Kruz A., Sessler D.I. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. N Engl J Med. 342:2000;161-167
103. Jordan D.C., Mallony H.D.C. Site of action of vancomycin on Staphylococcus aureus. Antimicrob Agents Chemother. 4:1964;489-494
104. Jordan D.C., Inniss W.E. Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin. Nature. 184:1959;1984-1985
105. Karchmer A.W. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med. 115:1991;739-741
106. Lowy F.D. Staphylococcus aureus infections. N Engl J Med. 339:1998;520-532
107. Ackerman B.H., Vannier A.M., Eudy E.B. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother. 36:1992;1766-1769
108. Chambers H.F. Parenteral antibiotics for the treatment of bacteremia and other serious staphylococcal infections. Crossley K.B., Archer G.L. The Staphylococci in human disease. 1997;583-601 Churchill Livingstone, New York
109. Levine D.P., Cushing R.D., Jui J., Brown W.J. Community acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med. 97:1982;330-338
110. Levine D.P., Fromm B.S., Reddy B.R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med. 115:1991;674-680
111. Menda K.B., Gorbach S.L. Favorable experience with bacterial endocarditis in heroin addicts. Ann Intern Med. 78:1973;25-32
112. Abrams B., Sklaver A., Hoffman T., Greenman R. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med. 90:1979;789-791
113. Rajasekharaiah K.R., Rice T., Rao V.S., Marsh D., Ramakrishna B., Kallick C.A. Clinical significance of tolerant strains of Staphylococcus aureus in patients with endocarditis. Ann Intern Med. 93:1980;796-801
114. Korzeniowski O., Sande M.A. the National Collaborative Endocarditis Study Group Combination antimicrobial therapy of Staphylococcus aureus endocarditis in parenteral drug addicts and nonaddicts. Ann Intern Med. 97:1982;496-503
115. Korzeniowski O., Sande M.A. The National Collaborative Endocarditis Study Group Combination antimicrobial therapy of Staphylococcus aureus endocarditis in parenteral drug addicts and nonaddicts. Ann Intern Med. 97:1982;496-503
116. Hirano L., Bayer A.S. Beta-lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase- producing oxacillin-resistant staphylococci. Antimicrob Agents Chemother. 35:1991;685-690
117. Update. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep. 46:1997;813-815. erratum: MMWR Morb Mortal Wkly Rep 1997;46:851
118. Vancomycin. Gilbert D.N., Moellering R.C., Sande M.A. The Sanford guide to antimicrobial therapy. 29th edition:1999;67 Antimicrobial Therapy, Inc., Hyde Park (VT)
119. Drew R.H., Perfect J.R., Srinath L., Kurkimilis E., Dowzicky M., Talbot G.H. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the synercid emergency-use group. Antimicrob Agents Chemother. 46:2000;775-784
120. Fagon J.-Y., Patrick H., Haas D.W., Torres A., Gibert C., Cheadle W.G., et al. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin-dalfopristin versus vancomycin. Am J Respir Crit Care Med. 161:2000;753-762
121. Rubinstein E., Prokocimer P., Talbot G.H. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother. 44(Suppl A):1999;37-46
122. Jones R.N., Johnson D.M., Erwin M.E. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinone antibiotics. Antimicrob Agents Chemother. 40:1996;720-726
123. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 34:2002;1481-1490
124. Rubinstein E., Cammarata S.K., Oliphant T.H., Wunderink R.G. the Linezolid Nosocomial Pneumonia Study Group Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 32:2001;402-412
125. Ruiz M.E., Guerrero I.C., Tuazon C.U. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis. 35:2002;1018-1020
126. Oramas-Shirey M.P., Buchanan L.V., Dileto-Fang C.L., Dailey C.F., Ford C.W., Batts D.H., et al. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother. 47:2001;349-352
127. Waldrep T.W., Skiest D.J. Linezolid-induced anemia and thrombocytopenia. Pharmacother. 22:2002;109-112
128. Green S.L., Maddox J.C., Huttenbach E.D. Linezolid and reversible myelosuppression. JAMA. 285:2001;1291-1293
129. Attassi K., Hershberger E., Alam R., Zervos M.J. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 34:2002;695-698
130. Orrick J.J., Johns T., Janelle J., Ramphal R. Thrombocytopenia secondary to linezolid administration: what is the risk? Clin Infect Dis. 35:2002;348-349
131. Lavery S., Ravi H., McDaniel W.W., Pushkin Y.R. Linezolid and serotonin syndrome. Psychosomatics. 42:2001;432-434
132. Wigen C.L., Goetz M.B. Serotonin syndrome and linezolid. Clin Infect Dis. 34:2002;1651-1652
133. Markowitz N., Quinn E.L., Saravolatz L.D. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 117:1992;390-398
134. Scheld W.M., Keeley J.M., Field M.R., Brodeur J.P. Co-trimoxazole versus nafcillin in the therapy of experimental meningitis due to Staphylococcus aureus. J Antimicob Chemother. 19:1987;647-658
135. Tedesco K.L., Rybak M.J. Daptomycin. Pharmacotherapy. 24:2004;41-57
136. Cha R., Brown W.J., Rybak M.J. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 47:2003;3960-3963
137. Rybak M.J., Hershberger E., Moldovan T., Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother. 44:2000;1062-1066
138. Wise R., Gee T., Andrews J.M., Dvorchik B., Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother. 46:2002;31-33
139. Eliopoulos G.M. Newer glycopeptides and derivatives for MRSA [abstract 1179]. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002. 2002;Excerpta Medica, San Diego (CA), Hillsborough (NJ)
140. Sesoko S., Umemura K., Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males [abstract A-1403]. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002. 2002;Excerpta Medica, San Diego (CA), Hillsborough (NJ)
141. Climo M.W., Patron R.L., Goldstein B.P., Archer G. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother. 42:1998;1355-1360
142. Haroche J., Morvan A., Davi M., Allignet J., Bimet F., El Solh N. Clonal diversity among streptogramin A-resistant Staphylococcus aureus isolates collected in French hospitals. J Clin Microbiol. 41:2003;586-591
143. Werner G., Cuny C., Schmitz F.J., Witte W. Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol. 39:2001;3586-3590
144. Imahara S.D., Nathens A.B. Antimicrobial strategies in surgical critical care. Curr Opin Crit Care. 9:2003;286-291
145. Feucht C.L., Rice L.B. An interventional program to improve antibiotic use. Ann Pharmacother. 37:2003;646-651
146. Pujol M., Gudiol F. Evidence for antibiotic cycling in control of resistance. Curr Opin Infect Dis. 14:2001;711-715
147. Solomkin J.S., Bjornson H.S., Cainzos M., Dellinger E.P., Dominioni L., Eidus R., et al. A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients. Am J Surg. 187:2004;134-145
148. Hiramatsu K., Cui L., Kuroda M., Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 9:2001;486-493
149. Oliveira D.C., Tomasz A., de Lencastre H. The evolution of pandemic clones of Methicillin-resistant Staphylococcus aureus: identification of two ancestral genetic backgrounds and the associated mec elements. Microb Drug Resist. 7:2001;349-361
150. Enright M.C., Robinson D.A., Randle G., Feil D.J., Grundmann H., Spratt B.G. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A. 99:2002;7687-7692
151. Wilton P., Smith R., Coast J., Millar M. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy. 7:2002;111-117
152. Muto C.A., Jernigan J.A., Ostrowsky B.E., Richet H.M., Jarvis W.R., Boyce J.M., et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 24:2003;362-386
153. Bager F. DANMAP 98: consumption of antimicrobial agents and occurrence of antimicrobials in bacteria from food animals, food and humans in Denmark. 1998;Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency, Danish Veterinary Laboratory, Copenhagen (Denmark)
154. Salmenlinna S., Lyytikainen O., Kotilainen P., Scotford R., Siren E., Vuopio-Varkila J. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Finland. Eur J Clin Microbiol Infect Dis. 19:2000;101-107
155. Verhoef J., Beaujean D., Blok H., Baars A., Meyler A., van der Werken C., et al. A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 18:1999;461-466
156. Chaix C., Durand-Zaleski I., Alberti C., Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA. 282:1999;1745-1751
157. Karchmer T.B., Durbin L.J., Simonton B.M., Farr B.M. Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect. 51:2002;126-132
158. Lucet J.C., Chevret S., Durand-Zaleski I., Chastang C., Regnier B. Multicenter Study Group Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med. 163:2003;181-188